Altus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders. It utilizes its proprietary protein crystallization technology to develop protein therapies. The company’s lead product candidates include ALTU-135, a Phase II completed clinical trial product, which is an orally-administered enzyme replacement therapy for the treatment of malabsorption; and ALTU-238, a Phase II clinical trial product, used for the treatment of growth hormone deficiency in adults. It also has a pipeline of product candidates in preclinical research and development that include ALTU-237, which is designed to treat hyperoxalurias; and ALTU-236, which is designed to treat phenylketonuria. The company has strategic alliances with Cystic Fibrosis Foundation Therapeutics, Inc. for the development of ALTU-135; and Dr. Falk Pharma GmbH for commercializing ALTU-135 in Europe, the countries of the former Soviet Union, Israel, and Egypt. Altus Pharmaceuticals, formerly known as Altus Biologics, Inc., was co-founded by Peter L. Lanciano in 1992, and changed its name to Altus Pharmaceuticals, Inc. in 2004. The company is based in Cambridge, Massachusetts.